Potential new clinical therapies for Chagas disease

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 317-325

  Bustamante, Juan M ^a   Tarleton, Rick L ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Chagas disease; Clinical trials; Drug discovery; Drug treatment; Trypanosoma cruzi

Indexed keywords

ALLOPURINOL; BENZNIDAZOLE; CLOMIPRAMINE; CYSTEINE PROTEINASE INHIBITOR; FEXINIDAZOLE; HEXOKINASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; ITRACONAZOLE; KETOCONAZOLE; NITRO DERIVATIVE; POSACONAZOLE; PURINE; RAVUCONAZOLE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; TIPIFARNIB; TRYPANOTHIONE; ANTITRYPANOSOMAL AGENT; NIFURTIMOX; NITROIMIDAZOLE DERIVATIVE; STEROL;

ALTERNATIVE MEDICINE; CHAGAS DISEASE; DRUG TREATMENT FAILURE; FATTY ACID METABOLISM; HOST PATHOGEN INTERACTION; HUMAN; INDUCED RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARASITE LOAD; POVERTY; REVIEW; STEROL SYNTHESIS; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PARASITOLOGY; PROCEDURES;

CHAGAS DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; NIFURTIMOX; NITROIMIDAZOLES; STEROLS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84898902010     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.909282     Document Type: Review

References (107)

1. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115(1-2):55-68
2. Hotez PJ, Bottazzi ME, Franco-Paredes C, et al. The neglected tropical diseases of latin america and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2008;2(9):e300
3. Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas' Disease in the United States. Clin Microbiol Rev 2011;24(4):655-81
4. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010;115(1-2):22-7
5. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375(9723):1388-402
6. Reithinger R, Tarleton RL, Urbina JA, et al. Eliminating Chagas disease: challenges and a roadmap. BMJ 2009;338:b1283
7. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002;97(1):3-24
8. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009;7(2): 157-63
9. Nicoll-Griffith DA. Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease. Expert Opin Drug Discov 2012;7(4):353-66
10. Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis 2010;23(6):609-16
11. Chagas Drug Discovery Consortium. Available from: http://sites.google. com/site/ chagasddc [Last accessed 30 January 2014]
12. Rohmer M, Bouvier P, Ourisson G. Molecular evolution of biomembranes: structural equivalents and phylogenetic precursors of sterols. Proc Natl Acad Sci USA 1979;76(2):847-51
13. Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi sterol 14alpha-demethylase (CYP51). Adv Parasitol 2011;75:65-87
14. de Almeida EA, Silva EL, Guariento ME, et al. Aetiological treatment with itraconazole or ketoconazole in individuals with Trypanosoma cruzi/HIV co-infection. Ann Trop Med Parasitol 2009;103(6):471-6
15. Toledo MJ, Bahia MT, Carneiro CM, et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother 2003;47(1): 223-30
16. Araujo MS, Martins-Filho OA, Pereira ME, Brener Z. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother 2000; 45(6):819-24
17. Urbina JA, Lira R, Visbal G, Bartroli J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 2000;44(9): 2498-502
18. Urbina JA, Payares G, Molina J, et al. Cure of short- and long-term experimental Chagas' disease using D0870. Science 1996; 273(5277):969-71
19. Corrales M, Cardozo R, Segura MA, et al. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother 2005;49(4):1556-60
20. Molina J, Martins-Filho O, Brener Z, et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000;44(1):150-5
21. Ferraz ML, Gazzinelli RT, Alves RO, et al. The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007;51(4): 1359-64
22. Clinical trial for the treatment of chronic chagas disease with posaconazole and benznidazole (CHAGASAZOL). Hospital Universitari Vall d'Hebron Research Institute. Clinicaltrials.gov: A service of the U.S. National Institutes of Health. Identifier: NCT01162967. Available from: http://clinicaltrials.gov/ct2/show/ NCT01162967 [Last accessed 30 January 2014]
23. John Vandeberg, Chagas Drug Discovery Consortium 2012 Meeting. Available from: https://sites.google.com/site/chagasddc/ [Last accessed 30 January 2014]
24. Israel Molina. Chagas Drug Discovery Consortium 2012 Meeting. Available from: https://sites.google.com/site/chagasddc/and International Congress of Tropical Medicine. Available from: http:// ictmm2012.ioc.fiocruz.br/program-25- sept. html [Last accessed 30 January 2014]
25. A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (STOP CHAGAS). Merck Sharp & Dohme Corp. Clinicaltrials.gov: A service of the U.S. National Institutes of Health. Identifier: NCT01377480. Available from: http:// clinicaltrials.gov/ show/NCT01377480 [Last accessed 30 January 2014]
26. Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54(7):2979-86
27. Urbina JA, Payares G, Sanoja C, et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrob Agents 2003;21(1):27-38
28. Proof-of-Concept Study of E1224 to treat adult patients with chagas disease. Drugs for neglected diseases initiative. Clinicaltrials. gov: A service of the U.S. National Institutes of Health. Identifier: NCT01489228. Available from: http:// clinicaltrials.gov/show/NCT01489228 [Last accessed 30 January 2014]
29. Kraus JM, Tatipaka HB, McGuffin SA, et al. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem 2010;53(10):3887-98
30. Buckner FS, Bahia MT, Suryadevara PK, et al. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother 2012;56(9):4914-21
31. Soeiro Mde N, de Souza EM, da Silva CF, et al. In vitro and in vivo studies of the antiparasitic activity of sterol 14alpha-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother 2013;57(9):4151-63
32. Villalta F, Dobish MC, Nde PN, et al. VNI cures acute and chronic experimental Chagas disease. J Infect Dis 2013;208(3): 504-11
33. Gunatilleke SS, Calvet CM, Johnston JB, et al. Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis 2012;6(7):e1736
34. Bontempi E, Martinez J, Cazzulo JJ. Subcellular localization of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 1989;33(1):43-7
35. Cazzulo JJ, Cazzulo FM, Martinez J, Franke dCB. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Biophys Acta 1990;1037(2):186-91
36. Engel JC, Doyle PS, Hsieh I, McKerrow JH. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998;188(4):725-34
37. McKerrow JH. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int J Parasitol 1999;29(6):833-7
38. Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005;49(12):5160-1
39. Brak K, Kerr ID, Barrett KT, et al. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. J Med Chem 2010;53(4):1763-73
40. Ndao M, Beaulieu C, Black WC, et al. Reversible cysteine protease inhibitors show promise for a chagas cure. Antimicrob Agents Chemother 2014;58(2):1167-78
41. Docampo R, de Souza W, Miranda K, et al. Acidocalcisomes - conserved from bacteria to man. Nat Rev Microbiol 2005; 3(3):251-61
42. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289(5484):1508-14
43. Bergstrom JD, Bostedor RG, Masarachia PJ, et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373(1):231-41
44. Montalvetti A, Bailey BN, Martin MB, et al. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem 2001; 276(36):33930-7
45. Bouzahzah B, Jelicks LA, Morris SA, et al. Risedronate in the treatment of Murine Chagas' disease. Parasitol Res 2005;96(3): 184-7
46. Garzoni LR, Waghabi MC, Baptista MM, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004;23(3):286-90
47. Sanz-Rodriguez CE, Concepcion JL, Pekerar S, et al. Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J Biol Chem 2007;282(17):12377-87
48. Hudock MP, Sanz-Rodriguez CE, Song Y, et al. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem 2006;49(1):215-23
49. Aripirala S, Szajnman SH, Jakoncic J, et al. Design, synthesis, calorimetry, and crystallographic analysis of 2- alkylaminoethyl-1,1- bisphosphonates as inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. J Med Chem 2012; 55(14):6445-54
50. Demoro B, Caruso F, Rossi M, et al. Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. Dalton Trans 2012; 41(21):6468-76
51. Recher M, Barboza AP, Li ZH, et al. Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents. Eur J Med Chem 2013;60:431-40
52. Rodrigues-Poveda CA, Gonzalez-Pacanowska D, Szajnman SH, Rodriguez JB. 2-alkylaminoethyl- 1,1-bisphosphonic acids are potent inhibitors of the enzymatic activity of Trypanosoma cruzi squalene synthase. Antimicrob Agents Chemother 2012;56(8): 4483-6
53. Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol 1992;46:695-729
54. Schmidt A, Krauth-Siegel RL. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr Top Med Chem 2002;2(11):1239-59
55. de Oliveira RB, Vaz AB, Alves RO, et al. Arylfurans as potential trypanosoma cruzi trypanothione reductase inhibitors. Mem Inst Oswaldo Cruz 2006;101(2):169-73
56. Meiering S, Inhoff O, Mies J, et al. Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. J Med Chem 2005;48(15):4793-802
57. Bustamante JM, Presti MS, Rivarola HW, et al. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int J Antimicrob Agents 2007; 29(6):733-7
58. Lo Presti MS, Rivarola HW, Bustamante JM, et al. Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice. Int J Antimicrob Agents 2004;23(6):634-6
59. Rivarola HW, Fernandez AR, Enders JE, et al. Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice. Ann Trop Med Parasitol 1999;93(7): 695-702
60. Fauro R, Lo Presti S, Bazan C, et al. Use of clomipramine as chemotherapy of the chronic phase of Chagas disease. Parasitology 2013;140(7):917-27
61. Paulino M, Iribarne F, Dubin M, et al. The chemotherapy of chagas' disease: an overview. Mini Rev Med Chem 2005; 5(5):499-519
62. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003;19(11):495-501
63. Gobbi P, Baez A, Lo Presti MS, et al. Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi. Parasitol Res 2010;107(5):1279-83
64. Gobbi P, Lo Presti MS, Fernandez AR, et al. Allopurinol is effective to modify the evolution of Trypanosoma cruzi infection in mice. Parasitol Res 2007;101(5):1459-62
65. Gallerano RR, Sosa RR. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy]. Rev Fac Cien Med Univ Nac Cordoba 2000;57(2):135-62
66. Apt W, Arribada A, Zulantay I, et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann Trop Med Parasitol 2003;97(1):23-9
67. Rassi A, Luquetti AO, Rassi A Jr, et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg 2007;76(1):58-61
68. Freymann DM, Wenck MA, Engel JC, et al. Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi. Chem Biol 2000;7(12):957-68
69. Medrano FJ, Wenck MA, Eakin AE, Craig SP 3rd. Functional roles for amino acids in active site loop II of a hypoxanthine phosphoribosyltransferase. Biochim Biophys Acta 2003;1650(1-2):105-16
70. Raviolo MA, Solana ME, Novoa MM, et al. Synthesis, physicochemical properties of allopurinol derivatives and their biological activity against Trypanosoma cruzi. Eur J Med Chem 2013;69:455-64
71. Minning TA, Weatherly DB, Atwood J 3rd, et al. The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics 2009;10:370
72. Atwood JA 3rd, Weatherly DB, Minning TA, et al. The Trypanosoma cruzi proteome. Science 2005;309(5733):473-6
73. Collins MH, Craft JM, Bustamante JM, Tarleton RL. Oral exposure to Trypanosoma cruzi elicits a systemic CD8 T cell response and protection against heterotopic challenge. Infect Immun 2011; 79(8):3397-406
74. Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother 2012;56(1): 115-23
75. Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 2011;286(15): 13088-95
76. Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008;105(13):5022-7
77. Walton MI, Workman P. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 1987;36(6): 887-96
78. Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1988;1(1):19-33
79. Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel 3-nitro-1H- 1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies. Future Med Chem 2013;5(15):1763-76
80. Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel 3-nitro-1H- 1,2,4-triazole-based piperazines and 2- amino-1,3-benzothiazoles as antichagasic agents. Bioorg Med Chem 2013;21(21): 6600-7
81. Canavaci AM, Bustamante JM, Padilla AM, et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis 2010;4(7):e740
82. Raether W, Seidenath H. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Ann Trop Med Parasitol 1983; 77(1):13-26
83. Papadopoulou MV, Trunz BB, Bloomer WD, et al. Novel 3-nitro-1H- 1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents. J Med Chem 2011;54(23):8214-23
84. Bahia MT, de Andrade IM, Martins TA, et al. Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Negl Trop Dis 2012;6(11):e1870
85. Human African Trypanosomiasis: first in Man Clinical Trial of a New Medicinal Product, the Fexinidazole. Drugs for Neglected Diseases Initiative. Clinicaltrials. gov: A service of the U.S. National Institutes of Health. Identifier: NCT00982904. Available from: http:// clinicaltrials.gov/show/ NCT00982904 [Last accessed 30 January 2014]
86. Jacobs RT, Plattner JJ, Keenan M. Boron-based drugs as antiprotozoals. Curr Opin Infect Dis 2011;24(6):586-92
87. Baker SJ, Ding CZ, Akama T, et al. Therapeutic potential of boron-containing compounds. Future Med Chem 2009;1(7): 1275-88
88. Seiradake E, Mao W, Hernandez V, et al. Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles. J Mol Biol 2009;390(2):196-207
89. Jacobs RT, Plattner JJ, Nare B, et al. Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. Future Med Chem 2011;3(10):1259-78
90. Jacobs RT, Nare B, Wring SA, et al. SCYX- 7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 2011; 5(6):e1151
91. Human African Trypanosomiasis: first in Man Clinical Trial of a New Medicinal Product, the SCYX-7158. Drugs for neglected diseases initiative. Clinicaltrials. gov: A service of the U.S. National Institutes of Health. Identifier: NCT01533961. Available from: http:// clinicaltrials.gov/show/ NCT01533961 [Last accessed 30 January 2014]
92. Bustamante JM, Craft JM, Crowe BD, et al. New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice. J Infect Dis 2014;209(1):150-62
93. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002;137(5 Pt 2):381-433
94. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205(Suppl 2):S241-9
95. WHO. Antimalarial drug combination therapy. Report of a WHO Technical Consultation. WHO; Geneva, Switzerland: 2001
96. Cencig S, Coltel N, Truyens C, Carlier Y. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome(R) in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents 2012;40(6):527-32
97. Diniz Lde F, Urbina JA, de Andrade IM, et al. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis 2013;7(8): e2367
98. Moreira da Silva R, Oliveira LT, Silva Barcellos NM, et al. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method. Antimicrob Agents Chemother 2012;56(6): 3344-8
99. Batista Dda G, Batista MM, de Oliveira GM, et al. Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo. PLoS One 2011;6(7):e22155
100. Grosso NL, Alarcon ML, Bua J, et al. Combined treatment with benznidazole and allopurinol in mice infected with a virulent Trypanosoma cruzi isolate from Nicaragua. Parasitology 2013;140(10):1225-33
101. Manne J, Snively CS, Levy MZ, Reich MR. Supply chain problems for Chagas disease treatment. Lancet Infect Dis 2012;12(3): 173-5
102. Navarro M, Norman FF, Perez-Molina JA, Lopez-Velez R. Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain. Am J Trop Med Hyg 2012;87(3):489-90
103. BENEFIT: evaluation of the Use of antiparasital drug (Benznidazole) in the treatment of chronic chagas' disease. population health research institute. Clinicaltrials.gov: A service of the U.S. National Institutes of Health. Identifier: NCT00123916. Available from: http:// clinicaltrials.gov/show/ NCT00123916 [Last accessed 30 January 2014]
104. Viotti R, de Noya BA, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother 2014;58(2): 635-9
105. Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Rev Anti Infect Ther 2007;5(4): 717-26
106. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144(10):724-34
107. Rodriguez A, Tarleton RL. Transgenic parasites accelerate drug discovery. Trends Parasitol 2012;28(3):90-2